BMY — Bristol-Myers Squibb Share News
0.000.00%
Last trade - 00:00- $123.73bn
- $155.78bn
- $48.19bn
Brief: Bristol Myers Squibb To Showcase Next-Generation Cancer Modalities And Leadership Across Solid Tumors At Esmo 2026
US RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Healthcare stocks rally as investors seek safety amid tech debt worries
AstraZeneca strikes $40 million AI drug discovery deal with insitro
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
Factbox: Pharma sector doubles down on AI to slash costs, timelines
US RESEARCH ROUNDUP-Essex Property Trust, Qualys, Vulcan Materials
US STOCKS ON THE MOVE-Microsoft, Salesforce, Bristol Myers
US STOCKS ON THE MOVE-Microsoft, C3.ai, Salesforce, Bristol Myers
Brief: Bristol Myers Squibb Announces Positive Topline Results From The Interim Analysis Of Phase 3 ACTION-1 For RYZ101, Rayzebio’S Radiopharmaceutical Therapy, In Patients With GEP-NETS
US STOCKS ON THE MOVE-Salesforce, Brown & Brown, IonQ, Harmony Biosciences
Bristol Myers rises on positive trial results for cancer and lung disease drugs
Bristol Myers radiopharma cancer drug slows rare tumor progression in study (updated)
Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial (updated)
Bristol Myers cancer therapy meets main goal in late-stage study
Bristol Myers' lung disease drug meets main goal in late-stage trial
Brief: Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant In Adults With Idiopathic Pulmonary Fibrosis Met Primary Endpoint
Atrium Therapeutics rallies after $50 mln equity raise
Factbox: Global healthcare companies invest billions to boost US presence